The Full Wiki

Fen-phen: Map


Wikipedia article:

Map showing all locations mentioned on Wikipedia article:

Fen-phen was an anti-obesity medication (an anorectic) which consisted of two drugs: fenfluramine and phentermine. Fenfluramine, and later, a related drug, dexfenfluramine, was marketed by American Home Products, now known as Wyeth, but were shown to cause potentially fatal pulmonary hypertension and heart valve problems, which eventually led to their withdrawal and legal damages of over $13 billion. Phentermine was not shown to cause harmful effects. Wyeth made drugs marketed as Redux and Pondimin, which were used as the fenfluramine half of the fen-phen combination formula.


Fenfluramine was first introduced in the 1970s, but was not popular because it only temporarily reduced weight by a few pounds. It was modestly selling until the 1990s when it was combined with phentermine and heavily-marketed. A similar drug, Aminorex, had caused severe lung damage and "provided reason to worry that similar drugs ... could increase the risk of a rare but often fatal lung disease, pulmonary hypertension". In 1994, Wyeth official Fred Wilson expressed concerns about fenfluramine's labeling containing only 4 cases of pulmonary hypertension when a total of 41 had been observed, but no action was taken until 1996. Wyeth introduced Redux (dexfenfluramine, the dextro isomer) in 1995 which it hoped would cause fewer adverse effects. However, the FDA's medical officer Leo Lutwak insisted upon a black box warning of pulmonary hypertension risks. After Lutwak refused to approve the drug, FDA management had someone else sign it and approved the drug with no black box warning for marketing in 1996. European regulators required a major warning of pulmonary hypertension risks.

In 1996, a case-control study in the New England Journal of Medicine found a 23-fold increase in pulmonary hypertension. Later in 1996 a thirty-year old woman developed heart problems after only a month of using it; when she died in February 1997, the Boston Herald devoted a frontpage article to her. In July 1997, after a technician observed heart abnormalities, researchers at the Mayo Clinicmarker released a report on 24 cases of rare valvular disease in women who took the Fen-phen combination therapy. The FDA alerted medical doctors that it had received nine additional reports of the same type, and requested all health care professionals to report any such cases to the agency’s MedWatch program, or to their respective pharmaceutical manufacturers. The FDA subsequently received 66 additional reports of heart valve disease, all primarily associated with Fen-phen. There were also reports of documented heart-valve problems in patients taking only either fenfluramine or dexfenfluramine. The FDA requested that the manufacturers of fenfluramine and dexfenfluramine stress the potential risk to the heart in the drugs' labeling and in patient package inserts. As of 1997, the FDA was continuing to receive reports of cardiac valvular disease in persons who had taken these drugs. This valvular disease typically involves the aortic and mitral valves.

After reports of valvular heart disease and pulmonary hypertension, primarily in women who had been undergoing treatment with Fen-phen, the Food and Drug Administration (FDA) requested its withdrawal from the market in September 1997.

The action was based on findings from doctor who had evaluated patients taking these two drugs with echocardiograms, a procedure that can test the functioning of heart valves. The findings indicated that approximately 30 percent of evaluated patients had abnormal echocardiograms, even though they had no symptoms. This percentage of abnormal test results was much higher than would be expected from a comparatively-sized sample of the population who had not been exposed to either fenfluramine or dexfenfluramine.


, Fen-phen is no longer widely available. In April 2005, American Lawyer magazine ran a cover story on the Fen-phen mass tort crisis, reporting that more than 50,000 product liability lawsuits had been filed by alleged Fen-phen victims. Estimates of total liability ran as high as $14 billion. As of February 2005, Wyeth was still in negotiations with injured parties, offering settlements of $5,000 to $200,000 to some of those who had sued, and stating they might offer more to those were most seriously injured. Thousands of injured persons rejected these offers, including 3,000 people represented by Pensacola lawyer Bryan Aylstock, another 3,000 people represented by Houston lawyer John O'Quinn, and another 8,000 people represented by Houston lawyer George Fleming. At the time, Wyeth announced it has set aside $21.1 billion (U.S.) to cover the cost of the lawsuits.

In 2008, three Kentuckymarker attorneys stood trial in U.S. federal district court for allegedly bilking millions of dollars appropriated to their clients in a Fen-phen settlement. One attorney, Melbourne Mills, Jr., was acquitted. On April 3, 2009, Shirley Cunnigham Jr and William Gallion were convicted on eight counts of wire fraud and one count of conspiracy to commit wire fraud for stealing money that should have gone to their 421 former clients. A jury decided that they must return $30 million. On August 13, 2009 William Gallion was sentenced to 25 years and Shirley Cunningham Jr sentenced to 20 years. The men were ordered to pay $127.7 million in restitution to their 421 former clients.

Also in 2008, 60 Minutes ran a broadcast about two Kentucky residents suing Wyeth because Fen-phen had caused permanent damage to their hearts.


  1. Avorn J. (2004). Powerful Medicines, pp. 71-84. Alfred A. Knopf.
  2. New York Times: Fen-Phen Case Lawyers Say They'll Reject Wyeth Offer, Feb. 17, 2005.

External links

Embed code:

Got something to say? Make a comment.
Your name
Your email address